Cancer biomarkers, companion diagnostics and personalized oncology

Biomarkers in Medicine

Volumn 5, Issue 3, 2011, Pages 277-279

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DRUG EFFICACY; FUNCTIONAL PROTEOMICS; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC VARIABILITY; HEALTH CARE QUALITY; HUMAN; HUMAN GENOME; MOLECULAR DIAGNOSIS; PATIENT CARE; PERSONALIZED MEDICINE; PREDICTION; PRODUCTIVITY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG TOXICITY; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958815219     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.29     Document Type: Review

References (14)

1. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002). (Pubitemid 34111379)
2. O'Dwyer ME, Druker BJ: STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol. 1, 207-211 (2000).
3. Ross JS, Ginsburg GS: Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discov. Today 7(16), 859-864 (2002).
4. Ross JS, Schenkein DP, Pietrusko R et al.: Targeted therapies for cancer 2004 Am. J. Clin. Pathol. 122(4), 598-609 (2004). (Pubitemid 39281258)
5. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M: Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4(2), e4439 (2009).
6. Wilke RA, Lin DW, Roden DM: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6(11), 904-916 (2007). (Pubitemid 350042398)
7. Ginsburg GS, McCarthy JJ: Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496 (2001). (Pubitemid 33063607)
8. Waters MD, Fostel JM: Toxicogenomics and systems toxicology: aims and prospects. Nat. Rev. Genet. 5(12), 936-948 (2004). (Pubitemid 39564256)
9. Monzon FA, Ogino S, Hammond ME et al.: The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med. 133, 1600-1606 (2009).
10. Sequist LV, Joshi VA, Jänne PA et al.: Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 12, 90-98 (2007). (Pubitemid 46143506)
11. Gerber DE, Minna JD: ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18, 548-551 (2010).
12. Smalley KS: PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr. Opin. Investig. Drugs 11, 699-706 (2010).
13. Macconaill LE, Garraway LA: Clinical implications of the cancer genome. J. Clin. Oncol. 28(35), 5219-5228 (2010).
14. Schilsky RL, Allen J, Benner J, Sigal E, McClellan M: Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist 15(5), 484-487 (2010).